1 / 69

ICAP MASTER SLIDE DECK Data reported through June 2009

ICAP MASTER SLIDE DECK Data reported through June 2009. Notes: Swaziland has not reported for the April-June 2009 quarter, so the results from January-March 2009 were carried over PFACTS Slides are based off of PFACTS Round 3 data. Number of ICAP-supported sites by activity, June 2009 (n=935).

fernando-castillo
Télécharger la présentation

ICAP MASTER SLIDE DECK Data reported through June 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICAP MASTER SLIDE DECK Data reported through June 2009 • Notes: • Swaziland has not reported for the April-June 2009 quarter, so the results from January-March 2009 were carried over • PFACTS Slides are based off of PFACTS Round 3 data

  2. Number of ICAP-supported sites by activity, June 2009 (n=935) Number of sites

  3. Number ofICAP-supported sites by country, June 2009 (n=935) Number of sites

  4. Care and treatment indicators

  5. What: Collects program and facility information on ICAP-supported care and treatment programs semi-annually Purpose: To describe the scope, diversity, and comprehensiveness of ICAP-supported care and treatment programs, and evaluate multi-level factors that influence program performance and patient-level outcomes Program and Facility Characteristics Tracking System (PFaCTS)

  6. Location and type of ICAP-supported HIV care and treatment sites (n=341, June 2008) n=149 n=192 % sites

  7. Proportion of ICAP-supported HIV care and treatment sites offering HIV-related services on site (n=341, June 2008) % sites with services

  8. Proportion of sites offering HIV-related services on-site, by number of services (n=341, June 2008)

  9. Proportion of ICAP-supported sites offering ≥4 HIV-related services on site (n=338, June 2008) Average =76% % sites with ≥4 services

  10. Proportion of ICAP-supported sites offering on-site patient support services, by type of service (n=323, June 2008) % sites with service

  11. Proportion of HIV care and treatment sites offering on-site patient support services, by number of services offered (n=323, June 2008)

  12. Proportion of ICAP-supported HIV care and treatment sites with ≥4 on-site patient support services (n=241) Average =45% % of sites with ≥ 4 services

  13. High proportion of ICAP-supported sites have access to key HIV-related laboratory assays % sites

  14. Proportion of ICAP-supported HIV care and treatment sites with access to laboratory assays by number of assays (n=336, June 2008)

  15. Proportion of ICAP-supported sites with access to key HIV-related lab assays (n=342, June 2008) Average =98% % sites Key laboratory assays include: CD4, CD4 percent, HIV-RNA, LFT, and blood chemistry. PCR laboratory tests are excluded.

  16. Proportion of ICAP-supported sites with access to PCR laboratory assays (n=325, June 2008) Average =92% % sites

  17. Mean number of full-time health care providers at HIV care and treatment sites (n=348, June 2008) Mean number of providers

  18. Mean number of outreach workers at ICAP-supported HIV care and treatment sites with outreach programs (n=183, June 2008) Mean number of outreach workers

  19. Trend in proportion of ICAP-supported sites offering on-site patient support services (n=175, June 2008) % of sites

  20. Prevention services are offered at most ICAP-supported sites (n=71, June 2008) % sites

  21. Care and treatment quarterly indicators

  22. HIV care and treatment services, as of June 2009

  23. New enrollment in care and treatment programs # of new patients

  24. Cumulative enrollment in ICAP-supported HIV care and treatment programs (currently reporting) 482 sites Cote d’Ivoire Swaziland Nigeria, Zambia Number of facilities Number of patients Lesotho, Rwanda, S. Africa, Tanzania 671,749 ever enrolled in care Ethiopia Mozambique 327,092 ever initiated ART

  25. Cumulative pediatric enrollment in ICAP-supported HIV care and treatment programs (currently reporting) 482 sites Cote d’Ivoire Swaziland Nigeria, Zambia Number of facilities Number of patients Lesotho, Rwanda, S. Africa, Tanzania 69,575 ever enrolled in care Ethiopia Mozambique 30,859 ever initiated ART

  26. Cumulative enrollment in HIV care in ICAP-supported HIV care and treatment programs by country(n=671,749) Cote d’Ivoire Swaziland Zambia Nigeria Lesotho Tanzania Number of patients Kenya Rwanda Ethiopia South Africa Mozambique

  27. Cumulative enrollment on ART at ICAP-supported HIV care and treatment programs by country (n=327,092) Swaziland Zambia Cote d’Ivoire Nigeria Lesotho Tanzania Number of patients Kenya Rwanda Ethiopia South Africa Mozambique

  28. Cumulative person-years on ART at ICAP-supported care and treatment programs, as of June 2009 Cumulative person-years on ART

  29. Cumulative and current enrollment in ART care at ICAP-supported HIV care and treatment programsas of June 2009 (n= 327,092) Cumulative initiating ART Lost to follow up Reported dead Number of patients ART patients retained in care

  30. Cumulative enrollment in ICAP-supported HIV care and treatment programs by ART status, age, and sex, as of June 2009 Total ART enrollment (n=327,092) Total care enrollment (n=671,749) Men 15+ Women 15+ Children <15 Children<15 Men 15+ Women 15+

  31. Proportion of all enrolled patients who initiated ART in ICAP-supported treatment programs as of June 2009 % patients initiating ART n=10,526 n=86,116 n=41,237 n=58,766 n= 44,557 n=671,749 n=46,058 n=77,362 n=34,517 n=188,765 n=3,589 n=79,256

  32. Cumulative enrollment in HIV care and treatment programs by age and sex, as of June 2009 n=344,657 n=327,092 n=671,749 % patients

  33. Children represent 10% of those in care (cumulative as of June 2009) % patients in HIV care n=86,116 n=671,749 n=58,766 n=41,237 n=10,526 n=46,058 n= 44,557 n=3,589 n=77,362 n=35,517 n=188,765 n=79,256

  34. Children represent 9% of patients initiating ART (cumulative as of June 2009) % patients on ART n=37,054 n=26,999 n=327,092 n=21,192 n=4,205 n=43,823 n= 24,405 n=22,679 n=35,174 n=2,066 n=46,309 n=63,186

  35. Cumulative pediatric HIV care enrollment, as of June 2009 n=152 n=4,688 n=6,790 n=3,404 n=9,654 n=1,478 n=16,355 n=3,786 n=10,411 n=5,830 n=69,575 n=7,027 % pediatric patients in HIV care

  36. Cumulative pediatric ART enrollment, as of June 2009 n=3,460 n=5,600 n=3,604 n=3,217 n=2,570 n=4,047 n=874 n=1,590 n=4,161 n=30,859 n=1,651 n=85 % pediatric patients on ART

  37. ART initiation among patients eligible for ART in ICAP-supported programs, April-June 2009 n=425 n=3,846 n=5,644 n=2,768 n=1,156 n=1,433 n=160 n=2,705 n=2,002 n=3,671 n=26,352 n=2,542 % patients eligible for ART Eligible, but not started: Number in HIV care during the quarter and eligible for ART but NOT started ART by the end of the quarter.” Eligible, started: All those who were eligible and started on ART during the reporting quarter.

  38. ART regimens distributed in ICAP-supported HIV care and treatment programs, April-June 2009

  39. ART regimens distributed to adults in ICAP-supported HIV care and treatment programs, April-June 2009 * In South Africa, D4T-3TC-LPV/r , ZDV-ddl-LPV/r , and ABC-ddl-LPV/r are prescribed as a first-line regimen for pediatric patients.

  40. ART regimens distributed to children in ICAP supported HIV care and treatment programs, April-June 2009

  41. Proportion of patients with CD4 count at baseline, 6, and 12 months after ART initiation % patients with CD4 count n=8,497 n=13,420 n=7,420 n=9,921 n=25,854 n=10,683 n=9,557 n=29,342 n=114,694

  42. Robust and sustained increases in median CD4 count among cohorts of patients initiating ART CD4 Cell Count (cells/ul) n=8,497 13,420 n=10,683 n=29,342 n=7,420 n=25,854 n=114,694 n=9,557 n=9,921

  43. Change in Median CD4 count at 6 and12 months of ART, as of June 2009 Change in median CD4 count (cells/µL)

  44. Status of ART patients at ICAP-supported HIV care and treatment programs as of June 2009 (n= 327,092) 10.3% per year on ART Lost to Follow-up 5.3% per year on ART Reported Dead .59% per year on ART Stopped ART *Includes patients who transferred out while on ART.

  45. Reasons for ART discontinuation in ICAP-supported HIV facilities as of June 2009 n=573 n=5,909 n=167 n=6,520 n=13,541 n=9,277 n=9,124 n=3,200 n=3,511 n=8.078 n=1,941 % of Discontinuing Patients

  46. PMTCT indicators

  47. Pregnant women counseled and tested inICAP-supported PMTCT programs, cumulative as of June 2009 # of Women

  48. Pregnant women counseled and tested inICAP-supported PMTCT programs, cumulative as of June 2009 % Women

  49. Pregnant women counseled and tested and prophylaxed in PMTCT programs over time # of Women

  50. Pregnant women counseled and tested inICAP-supported PMTCT programs over time % Women First ANC n=60,520 n=67,421 n=83,315 n=83,431 n=91,663

More Related